Literature DB >> 16914724

Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state.

Jason H Kurzer1, Pipsa Saharinen, Olli Silvennoinen, Christin Carter-Su.   

Abstract

The tyrosine kinase Janus kinase 2 (JAK2) transduces signaling for the majority of known cytokine receptor family members and is constitutively activated in some cancers. Here we examine the mechanisms by which the adapter proteins SH2-Bbeta and APS regulate the activity of JAK2. We show that like SH2-Bbeta, APS binds JAK2 at multiple sites and that binding to phosphotyrosine 813 is essential for APS to increase active JAK2 and to be phosphorylated by JAK2. Binding of APS to a phosphotyrosine 813-independent site inhibits JAK2. Both APS and SH2-Bbeta increase JAK2 activity independent of their N-terminal dimerization domains. SH2-Bbeta-induced increases in JAK2 dimerization require only the SH2 domain and only one SH2-Bbeta to be bound to a JAK2 dimer. JAK2 mutations and truncations revealed that amino acids 809 to 811 in JAK2 are a critical component of a larger regulatory region within JAK2, most likely including amino acids within the JAK homology 1 (JH1) and JH2 domains and possibly the FERM domain. Together, our data suggest that SH2-Bbeta and APS do not activate JAK2 as a consequence of their own dimerization, recruitment of an activator of JAK2, or direct competition with a JAK2 inhibitor for binding to JAK2. Rather, they most likely induce or stabilize an active conformation of JAK2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914724      PMCID: PMC1592834          DOI: 10.1128/MCB.00570-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  54 in total

1.  Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.

Authors:  P Saharinen; K Takaluoma; O Silvennoinen
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

2.  Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases.

Authors:  Y J Zhou; M Chen; N A Cusack; L H Kimmel; K S Magnuson; J G Boyd; W Lin; J L Roberts; A Lengi; R H Buckley; R L Geahlen; F Candotti; M Gadina; P S Changelian; J J O'Shea
Journal:  Mol Cell       Date:  2001-11       Impact factor: 17.970

3.  Vav2 activates Rac1, Cdc42, and RhoA downstream from growth factor receptors but not beta1 integrins.

Authors:  B P Liu; K Burridge
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

4.  Alternative splicing, gene localization, and binding of SH2-B to the insulin receptor kinase domain.

Authors:  K Nelms; T J O'Neill; S Li; S R Hubbard; T A Gustafson; W E Paul
Journal:  Mamm Genome       Date:  1999-12       Impact factor: 2.957

5.  SH2-B family members differentially regulate JAK family tyrosine kinases.

Authors:  Karen B O'Brien; John J O'Shea; Christin Carter-Su
Journal:  J Biol Chem       Date:  2001-12-18       Impact factor: 5.157

6.  SH2-B and APS are multimeric adapters that augment TrkA signaling.

Authors:  X Qian; D D Ginty
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

7.  Molecular cloning of the mouse APS as a member of the Lnk family adaptor proteins.

Authors:  M Iseki; S Takaki; K Takatsu
Journal:  Biochem Biophys Res Commun       Date:  2000-05-27       Impact factor: 3.575

8.  Four PSM/SH2-B alternative splice variants and their differential roles in mitogenesis.

Authors:  N Yousaf; Y Deng; Y Kang; H Riedel
Journal:  J Biol Chem       Date:  2001-08-13       Impact factor: 5.157

9.  Differential binding to and regulation of JAK2 by the SH2 domain and N-terminal region of SH2-bbeta.

Authors:  L Rui; D R Gunter; J Herrington; C Carter-Su
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

10.  SH2-B is required for both male and female reproduction.

Authors:  Satoshi Ohtsuka; Satoshi Takaki; Masanori Iseki; Kanta Miyoshi; Naomi Nakagata; Yuki Kataoka; Nobuaki Yoshida; Kiyoshi Takatsu; Akihiko Yoshimura
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

View more
  20 in total

1.  The SH2B1 adaptor protein associates with a proximal region of the erythropoietin receptor.

Authors:  Mojib Javadi; Edda Hofstätter; Natalie Stickle; Bryan K Beattie; Robert Jaster; Christin Carter-Su; Dwayne L Barber
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

2.  SH2B1--the adaptor protein that could.

Authors:  Streamson Chua
Journal:  Endocrinology       Date:  2010-09       Impact factor: 4.736

Review 3.  SH2B1 regulation of energy balance, body weight, and glucose metabolism.

Authors:  Liangyou Rui
Journal:  World J Diabetes       Date:  2014-08-15

4.  Critical role of the Src homology 2 (SH2) domain of neuronal SH2B1 in the regulation of body weight and glucose homeostasis in mice.

Authors:  David L Morris; Kae Won Cho; Liangyou Rui
Journal:  Endocrinology       Date:  2010-05-19       Impact factor: 4.736

5.  Phosphorylation of the Unique C-Terminal Tail of the Alpha Isoform of the Scaffold Protein SH2B1 Controls the Ability of SH2B1α To Enhance Nerve Growth Factor Function.

Authors:  Ray M Joe; Anabel Flores; Michael E Doche; Joel M Cline; Erik S Clutter; Paul B Vander; Heimo Riedel; Lawrence S Argetsinger; Christin Carter-Su
Journal:  Mol Cell Biol       Date:  2018-02-27       Impact factor: 4.272

6.  Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.

Authors:  Sigal Gery; Qi Cao; Saskia Gueller; Hongtao Xing; Ayalew Tefferi; H Phillip Koeffler
Journal:  J Leukoc Biol       Date:  2009-03-17       Impact factor: 4.962

7.  Identification of steroid-sensitive gene-1/Ccdc80 as a JAK2-binding protein.

Authors:  Erin E O'Leary; Anna M Mazurkiewicz-Muñoz; Lawrence S Argetsinger; Travis J Maures; Hung T Huynh; Christin Carter-Su
Journal:  Mol Endocrinol       Date:  2013-02-28

8.  BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.

Authors:  Joji Nakayama; Mutsumi Yamamoto; Katsuhiko Hayashi; Hitoshi Satoh; Kenji Bundo; Masato Kubo; Ryo Goitsuka; Michael A Farrar; Daisuke Kitamura
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

9.  Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity.

Authors:  Megumi Funakoshi-Tago; Stéphane Pelletier; Hiroshi Moritake; Evan Parganas; James N Ihle
Journal:  Mol Cell Biol       Date:  2007-12-26       Impact factor: 4.272

Review 10.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.